Coronavirus COVID-19 – Executive Insights – Hospitalized COVID-19 Patients Executive Insights
The treatment landscape for COVID-19 continues to evolve rapidly. Even with vaccines having become available in the markets under study, intense ongoing research has also focused on approaches designed to reduce viral load and/or improve outcomes in hospitalized patients infected with SARS-CoV-2. While multiple therapies have been approved for the treatment of COVID-19 in the markets under study, most notably Gilead’s Veklury (remdesivir), treatment guidelines in these regions and/or available clinical evidence do not always support use of all available drugs. Nevertheless, given the high burden of this disease to healthcare systems worldwide, such treatments may be used, and underscoring the lingering high unmet need. Numerous drugs with diverse mechanisms of action are in clinical development for hospitalized COVID-19 patients, many of which are expected to launch in the next couple of years. The greater availability of treatment options will continue to transform the treatment landscape and help address the existing unmet need.
QUESTIONS ANSWERED
- What evidence exists for the use of current therapies as treatments for hospitalized COVID-19 patients?
- What is the treatment algorithm for hospital-treated COVID-19 patients?
- What is the state of the pipeline for drugs for hospitalized COVID-19 patients?
- What are the key areas of unmet need and opportunity for the treatment of hospitalized COVID-19 patients? What is the expected impact of therapies in development on the disease treatment and the market?
PRODUCT DESCRIPTION
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
KEY COMPANIES COVERED
Eli Lilly, Gilead, GlaxoSmithKline, Humanigen, Pfizer, Regeneron, Roche / Genentech, Sanofi, Sobi.
KEY DRUGS COVERED
Actemra / RoActemra (tocilizumab), bamlanivimab + etesevimab, Kevzara (sarilumab), Kineret (anakinra), Olumiant (baricitinib), ronapreve, Veklury (remdesivir), Xeljanz (tofacitinib), Xevudy (sotrovimab), Otezla (apremilast), lenzilumab, and other Phase III assets
GEOGRAPHY
United States, France, Germany, United Kingdom, Japan
PRIMARY RESEARCH
12 KOL interviews in September-October 2021
Shilpa Verma, B.Pharm., Manager, Healthcare Research & Data Analytics, Infectious, Niche, and Rare Diseases. She has more than 11 years of work experience in competitive intelligence and medical affairs. Her expertise is in infectious diseases and immuno-inflammatory diseases. She received her bachelor’s degree in pharmacy from the Indian Institute of Technology at Banaras Hindu University. She also has a postgraduate degree in business management from the Narsee Monjee Institute of Management Studies.
Prior to joining Clarivate, Ms. Verma worked for WNS and Evalueserve, where her clients included leading pharmaceutical companies. She is also an expert in HIV. She did her internship at AstraZeneca and has experience working in the quality control department.